DKCM
ADPT icon

Davidson Kempner Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Davidson Kempner Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-170,000
Closed -$5.09M – 164
2019
Q4 		$5.09M Buy
+170,000
New +$4.88M 0.11% 115
2019
Q3 		– Sell
-54,000
Closed -$2.59M – 165
2019
Q2 		$2.59M Buy
+54,000
New +$2.39M 0.03% 154

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Davidson Kempner Capital Management's ADPT Position: Q1 2020 in Review

Davidson Kempner Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2020, closing a stake of 170,000 shares — an estimated $5.09M sold.

Davidson Kempner Capital Management first reported a position in ADPT in Q2 2019 and held it in 2 quarters. The position peaked at $5.09M in Q4 2019. 147 funds tracked by Wall St. Rank hold ADPT as of Q1 2020.

  • Davidson Kempner Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 170,000 Adaptive Biotechnologies shares in Q1 2020, an estimated $5.09M.
  • Davidson Kempner Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 2 quarters.
  • Davidson Kempner Capital Management's Adaptive Biotechnologies position peaked at $5.09M in Q4 2019.
  • 147 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2020.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2020, filed 15 May 2020.